Literature DB >> 19191912

Virulence, immunopathology and transmissibility of selected strains of Mycobacterium tuberculosis in a murine model.

Brenda Marquina-Castillo1, Lourdes García-García, Alfredo Ponce-de-León, Maria-Eugenia Jimenez-Corona, Miriam Bobadilla-Del Valle, Bulmaro Cano-Arellano, Sergio Canizales-Quintero, Areli Martinez-Gamboa, Midori Kato-Maeda, Brian Robertson, Douglas Young, Peter Small, Gary Schoolnik, Jose Sifuentes-Osornio, Rogelio Hernandez-Pando.   

Abstract

After encounter with Mycobacterium tuberculosis, a series of non-uniform immune responses are triggered that define the course of the infection. Eight M. tuberculosis strains were selected from a prospective population-based study of pulmonary tuberculosis patients (1995-2003) based on relevant clinical/epidemiological patterns and tested in a well-characterized BALB/c mouse model of progressive pulmonary tuberculosis. In addition, a new mouse model of transmissibility consisting of prolonged cohousing (up to 60 days) of infected and naïve animals was tested. Four phenotypes were defined based on strain virulence (mouse survival, lung bacillary load and tissue damage), immunology response (cytokine expression determined by real-time polymerase chain reaction) and transmissibility (lung bacillary loads and cutaneous delayed-type hypersensitivity in naïve animals).We identified four clearly defined strain phenotypes: (1) hypervirulent strain with non-protective immune response and highly transmissible; (2) virulent strain, associated with high expression of proinflammatory cytokines (tumour necrosis factor and interferon) and very low anti-inflammatory cytokine expression (interleukins 4 and 10), which induced accelerated death by immunopathology; (3) strain inducing efficient protective immunity with lower virulence, and (4) strain demonstrating strong and early macrophage activation (innate immunity) with delayed participation of acquired immunity (interferon expression). We were able to correlate virulent and transmissible phenotypes in the mouse model and markers of community transmission such as tuberculin reactivity among contacts, rapid progression to disease and cluster status. However, we were not able to find correlation with the other two phenotypes. Our new transmission model supported the hypothesis that among these strains increased virulence was linked to increased transmission.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19191912      PMCID: PMC2747145          DOI: 10.1111/j.1365-2567.2008.03004.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  29 in total

1.  Mycobacterium tuberculosis drug resistance in a suburban community in southern Mexico.

Authors:  M L García-García; M E Jiménez-Corona; A Ponce-de-León; A Jiménez-Corona; M Palacios-Martínez; S Balandrano-Campos; L Ferreyra-Reyes; L Juárez-Sandino; J Sifuentes-Osornio; H Olivera-Díaz; J L Valdespino-Gómez; P M Small
Journal:  Int J Tuberc Lung Dis       Date:  2000-12       Impact factor: 2.373

2.  Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha /beta.

Authors:  C Manca; L Tsenova; A Bergtold; S Freeman; M Tovey; J M Musser; C E Barry; V H Freedman; G Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

3.  beta-Defensin gene expression during the course of experimental tuberculosis infection.

Authors:  Bruno Rivas-Santiago; Eduardo Sada; Victor Tsutsumi; Diana Aguilar-Leon; Juan Leon Contreras; Rogelio Hernandez-Pando
Journal:  J Infect Dis       Date:  2006-07-28       Impact factor: 5.226

4.  Clinical consequences and transmissibility of drug-resistant tuberculosis in southern Mexico.

Authors:  M L García-García; A Ponce de León; M E Jiménez-Corona; A Jiménez-Corona; M Palacios-Martínez; S Balandrano-Campos; L Ferreyra-Reyes; L Juárez-Sandino; J Sifuentes-Osornio; H Olivera-Díaz; J L Valdespino-Gómez; P M Small
Journal:  Arch Intern Med       Date:  2000-03-13

5.  Increased production of interleukin 4 by CD4+ and CD8+ T cells from patients with tuberculosis is related to the presence of pulmonary cavities.

Authors:  R van Crevel; E Karyadi; F Preyers; M Leenders; B J Kullberg; R H Nelwan; J W van der Meer
Journal:  J Infect Dis       Date:  2000-03       Impact factor: 5.226

6.  Type 2 cytokine gene activation and its relationship to extent of disease in patients with tuberculosis.

Authors:  G T Seah; G M Scott; G A Rook
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

7.  Genome-wide analysis of synonymous single nucleotide polymorphisms in Mycobacterium tuberculosis complex organisms: resolution of genetic relationships among closely related microbial strains.

Authors:  Michaela M Gutacker; James C Smoot; Cristi A Lux Migliaccio; Stacy M Ricklefs; Su Hua; Debby V Cousins; Edward A Graviss; Elena Shashkina; Barry N Kreiswirth; James M Musser
Journal:  Genetics       Date:  2002-12       Impact factor: 4.562

8.  Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains.

Authors:  R D Fleischmann; D Alland; J A Eisen; L Carpenter; O White; J Peterson; R DeBoy; R Dodson; M Gwinn; D Haft; E Hickey; J F Kolonay; W C Nelson; L A Umayam; M Ermolaeva; S L Salzberg; A Delcher; T Utterback; J Weidman; H Khouri; J Gill; A Mikula; W Bishai; W R Jacobs; J C Venter; C M Fraser
Journal:  J Bacteriol       Date:  2002-10       Impact factor: 3.490

9.  Reduced immunopathology and mortality despite tissue persistence in a Mycobacterium tuberculosis mutant lacking alternative sigma factor, SigH.

Authors:  Deepak Kaushal; Benjamin G Schroeder; Sandeep Tyagi; Tetsuyuki Yoshimatsu; Cherise Scott; Chiew Ko; Liane Carpenter; Jyoti Mehrotra; Yukari C Manabe; Robert D Fleischmann; William R Bishai
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-11       Impact factor: 11.205

10.  Tuberculosis-related deaths within a well-functioning DOTS control program.

Authors:  Maria De Lourdes García-García; Alfredo Ponce-De-León; Maria Cecilia García-Sancho; Leticia Ferreyra-Reyes; Manuel Palacios-Martínez; Javier Fuentes; Midori Kato-Maeda; Miriam Bobadilla; Peter Small; José Sifuentes-Osornio
Journal:  Emerg Infect Dis       Date:  2002-11       Impact factor: 6.883

View more
  26 in total

1.  Does M. tuberculosis genomic diversity explain disease diversity?

Authors:  Mireilla Coscolla; Sebastien Gagneux
Journal:  Drug Discov Today Dis Mech       Date:  2010

2.  Increased Foxp3 expression in guinea pigs infected with W-Beijing strains of M. tuberculosis.

Authors:  Shaobin Shang; Marisa Harton; Marcela Henao Tamayo; Crystal Shanley; Gopinath S Palanisamy; Megan Caraway; Edward D Chan; Randall J Basaraba; Ian M Orme; Diane J Ordway
Journal:  Tuberculosis (Edinb)       Date:  2011-07-06       Impact factor: 3.131

3.  Specific interaction between Mycobacterium tuberculosis lipoprotein-derived peptides and target cells inhibits mycobacterial entry in vitro.

Authors:  Marisol Ocampo; Hernando Curtidor; Magnolia Vanegas; Manuel A Patarroyo; Manuel E Patarroyo
Journal:  Chem Biol Drug Des       Date:  2014-07-10       Impact factor: 2.817

Review 4.  Advances in the understanding of Mycobacterium tuberculosis transmission in HIV-endemic settings.

Authors:  Julian S Peters; Jason R Andrews; Mark Hatherill; Sabine Hermans; Leonardo Martinez; Erwin Schurr; Yuri van der Heijden; Robin Wood; Roxana Rustomjee; Bavesh D Kana
Journal:  Lancet Infect Dis       Date:  2018-12-13       Impact factor: 25.071

5.  Virulence and immune response induced by Mycobacterium avium complex strains in a model of progressive pulmonary tuberculosis and subcutaneous infection in BALB/c mice.

Authors:  Mónica González-Pérez; Leonardo Mariño-Ramírez; Carlos Alberto Parra-López; Martha Isabel Murcia; Brenda Marquina; Dulce Mata-Espinoza; Yadira Rodriguez-Míguez; Guillermina J Baay-Guzman; Sara Huerta-Yepez; Rogelio Hernandez-Pando
Journal:  Infect Immun       Date:  2013-08-19       Impact factor: 3.441

6.  Construction and Characterization of the Mycobacterium tuberculosis sigE fadD26 Unmarked Double Mutant as a Vaccine Candidate.

Authors:  Rogelio Hernandez-Pando; Sung Jae Shin; Simon Clark; Stefano Casonato; Martin Becerril-Zambrano; Hongmin Kim; Francesca Boldrin; Dulce Mata-Espinoza; Roberta Provvedi; Ainhoa Arbues; Brenda Marquina-Castillo; Laura Cioetto Mazzabò; Jorge Barrios-Payan; Carlos Martin; Sang-Nae Cho; Ann Williams; Riccardo Manganelli
Journal:  Infect Immun       Date:  2019-12-17       Impact factor: 3.441

7.  Functional genetic diversity among Mycobacterium tuberculosis complex clinical isolates: delineation of conserved core and lineage-specific transcriptomes during intracellular survival.

Authors:  Susanne Homolka; Stefan Niemann; David G Russell; Kyle H Rohde
Journal:  PLoS Pathog       Date:  2010-07-08       Impact factor: 6.823

8.  Differential virulence and disease progression following Mycobacterium tuberculosis complex infection of the common marmoset (Callithrix jacchus).

Authors:  Laura E Via; Danielle M Weiner; Daniel Schimel; Philana Ling Lin; Emmanuel Dayao; Sarah L Tankersley; Ying Cai; M Teresa Coleman; Jaime Tomko; Praveen Paripati; Marlene Orandle; Robin J Kastenmayer; Michael Tartakovsky; Alexander Rosenthal; Damien Portevin; Seok Yong Eum; Saher Lahouar; Sebastien Gagneux; Douglas B Young; Joanne L Flynn; Clifton E Barry
Journal:  Infect Immun       Date:  2013-05-28       Impact factor: 3.441

9.  Spontaneous latency in a rabbit model of pulmonary tuberculosis.

Authors:  Selvakumar Subbian; Liana Tsenova; Paul O'Brien; Guibin Yang; Nicole L Kushner; Sven Parsons; Blas Peixoto; Dorothy Fallows; Gilla Kaplan
Journal:  Am J Pathol       Date:  2012-09-05       Impact factor: 4.307

10.  Immunotherapeutic effects of recombinant adenovirus encoding granulocyte-macrophage colony-stimulating factor in experimental pulmonary tuberculosis.

Authors:  A Francisco-Cruz; D Mata-Espinosa; S Estrada-Parra; Z Xing; R Hernández-Pando
Journal:  Clin Exp Immunol       Date:  2013-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.